Advanced Proteome Therapeutics Corporation announced that in continuing efforts to advance the field of Protein Modification Technologies, the company has filed a patent application this October on inventions related to its Swift Linkage Multivalent Technology (SMLT). This Patent, along with previous discoveries, represents a milestone in the company's development and is a significant step toward commercialization. This advanced technology is currently being applied internally to protein targets aimed at treating cancer, Crohn's disease, arthritis, obesity, atherothrombosis and plaque rupture. In conjunction with the company's internal progress, this patent filing allows the company to foster relationships with potential partners, and/or customers that desire to utilize APT technology to further the development of their own programs.

Advanced Proteome Therapeutics Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended April 30, 2009. For the quarter, the company's net loss before noncontrolling interest was $282,626 compared to $366,497 a year ago. Net loss was $230,726 or $0.01 per basic and diluted common share, compared to net loss of $260,321 or $0.01 per basic and diluted common share, a year ago. Net cash flows used in operating activities was $177,641 compared to $305,863 a year ago. Purchase of equipment was $102,603 compared to $12,447 a year ago. For the nine months, the company's net loss before noncontrolling interest was $911,062 compared to $1,105,152 a year ago. Net loss was $693,033 or $0.01 per basic and diluted common share, compared to net loss of $831,097 or $0.01 per basic and diluted common share, a year ago. Net cash flows used in operating activities was $684,206 compared to $799,534 a year ago. Purchase of equipment was $135,103 compared to $22,926 a year ago.

Advanced Proteome Therapeutics Corporation reported un-audited consolidated earnings results for the second quarter and six months ended January 31, 2009. For the quarter, the company reported net loss of $204,243 or $0.01 per basic and diluted share on revenue of $20,795 compared to net loss of $359,236 or $0.01 per basic and diluted share on revenue of $34,061 for the same period last year. Net cash used in operating activities of $227,926 compared to $360,160 reported for the same period last year. For the six months, the company reported net loss of $462,307 or $0.01 per basic and diluted share on revenue of $30,041 compared to net loss of $570,776 or $0.01 per basic and diluted share on revenue of $49,144 for the same period last year. Net cash used in operating activities of $503,023 compared to $493,671 reported for the same period last year.